Valentis (VLTS) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Valentis (VLTS)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: tuck who wrote (45)	4/17/2001 10:14:51 AM
From: keokalani'nui	Read Replies (1) of 81

Dr. Gillian did not want to move to Texas? Valentis to Consolidate Pre-Clinical Research And Development Activities BURLINGAME, Calif., April 17 /PRNewswire/ -- Valentis, Inc. (Nasdaq: VLTS - news) announced today that it will consolidate all of its PEGylation research activities from its facilities in London, England into its preclinical research and development center in The Woodlands, Texas. About 15 jobs will be eliminated in the closure of the London center, reducing the total Valentis headcount to approximately 110 people. James Green, the Company's commercial development director, was named as managing director of the London Center and will be responsible for the transfer of the technology to Texas over the next six months. This will allow Valentis to utilize the research and development capabilities already present in its Texas operations to more rapidly advance its products and partnerships in the PEGylation area.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next